AbbVie Inc. filed a lawsuit on February 11 2026 against the U.S. Department of Health and Human Services, challenging the Centers for Medicare & Medicaid Services’ decision to include Botox in the Medicare drug price negotiation program under the Inflation Reduction Act.
Botox is a cornerstone of AbbVie’s revenue mix. In 2025 the therapeutic product generated $3.77 billion and the cosmetic product $2.6 billion, together accounting for roughly 10 % of the company’s $61.16 billion in total revenue.
The company argues that Botox is a plasma‑derived product, a category explicitly excluded from the IRA’s negotiation program. AbbVie cites the presence of human serum albumin and other plasma proteins in its formulation as the basis for this classification.
CMS selected Botox for the 2028 negotiation cycle because it is a high‑cost drug with significant Medicare Part B utilization. The agency cited the drug’s $3.5 billion annual spend and the potential for price savings under the IRA as justification for its inclusion.
AbbVie is not the first pharmaceutical company to challenge the IRA. Other firms have sued over the negotiation program, but most have been unsuccessful. AbbVie’s lawsuit introduces a new legal angle focused on product classification that could influence future litigation.
CEO Robert Michael expressed disappointment that Botox was selected, noting it should have been excluded as a plasma‑derived product. Investors reacted to concerns about the aesthetics segment and the company’s Q1 2026 guidance, which fell short of consensus expectations.
The lawsuit adds a regulatory headwind that could reduce AbbVie’s revenue from Botox by an estimated amount. While the company’s strong performance in immunology and neuroscience provides a cushion, the legal action signals ongoing risk to its revenue mix.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.